1 in crypto Overview

The turnover of Shanghai, Shenzhen and Beijing exceeded 1 trillion yuan, 55.6 billion yuan more than the previous day. Up to now, the turnover of Shanghai, Shenzhen and Beijing exceeded 1 trillion yuan, 55.6 billion yuan more than the previous day. Among them, the turnover of Shanghai Stock Exchange was 394.6 billion yuan, that of Shenzhen Stock Exchange was 596.3 billion yuan, and that of Beizheng 50 was 11.1 billion yuan.Asia-Pacific Pharmaceuticals: The new specifications of cefmetazole sodium for injection were approved, and Asia-Pacific Pharmaceuticals announced that the company was approved by National Medical Products Administration, and the new specifications of cefmetazole sodium for injection were 0.5g and 2g, which further enriched the product categories on the basis of the original 1g specifications. The annual sales income of this drug in 2023 was 96.3946 million yuan, accounting for 22.92% of the company's operating income. New specifications are helpful to market promotion and competitiveness improvement, but drug production and sales are affected by policies and market environment, and there are uncertainties.Mitsubishi electric: We are discussing cooperation with Japanese domestic competitors to develop power chips. Qi Jianqi, president of mitsubishi electric, Japan, said in an interview that the company is discussing cooperation with Japanese domestic competitors to develop power chips. Qi Jianqi said that although the management widely supported the cooperation, the above discussion was blocked at the administrative level and no progress was made. Qi Jianqi pointed out that the power chip industry needs continuous technological innovation, and it is meaningful to cooperate while there is still a chance to win market share. "We should not compete with each other, but need to unite.".

Hite Bio: Two drugs are planned to be selected for national centralized drug procurement. Hite Bio announced that the company participated in the tenth batch of national centralized drug procurement. According to the selected results released by the joint procurement, roxatidine acetate hydrochloride and pentoxifylline injection for injection of the company are selected for this centralized procurement. These two drugs are suitable for the treatment of upper gastrointestinal bleeding and peripheral arterial diseases respectively. The procurement cycle is from the date of implementation of the selected results to December 31, 2027, during which medical institutions will give priority to the use of selected drugs. The company obtained the Drug Registration Certificate of the above drugs in 2024, but it has not generated sales revenue this year. This election will help to enhance the brand influence of the company and have a positive impact on the company's development.The turnover of Shanghai, Shenzhen and Beijing exceeded 1 trillion yuan, 55.6 billion yuan more than the previous day. Up to now, the turnover of Shanghai, Shenzhen and Beijing exceeded 1 trillion yuan, 55.6 billion yuan more than the previous day. Among them, the turnover of Shanghai Stock Exchange was 394.6 billion yuan, that of Shenzhen Stock Exchange was 596.3 billion yuan, and that of Beizheng 50 was 11.1 billion yuan.[The yield of 30-year treasury bonds fell below the 2% mark, and the active bonds of 30-year treasury bonds fell below 2% by 4.26bp, reaching 1.9999% as of press time.

The 30-year main contract of treasury bond futures rose to 0.62%, which continued to hit a new high. In addition, the 10-year main contract rose by 0.37%, the 5-year main contract rose by 0.27%, and the 2-year main contract rose by 0.09%, which was another record.Hite Bio: Two drugs are planned to be selected for national centralized drug procurement. Hite Bio announced that the company participated in the tenth batch of national centralized drug procurement. According to the selected results released by the joint procurement, roxatidine acetate hydrochloride and pentoxifylline injection for injection of the company are selected for this centralized procurement. These two drugs are suitable for the treatment of upper gastrointestinal bleeding and peripheral arterial diseases respectively. The procurement cycle is from the date of implementation of the selected results to December 31, 2027, during which medical institutions will give priority to the use of selected drugs. The company obtained the Drug Registration Certificate of the above drugs in 2024, but it has not generated sales revenue this year. This election will help to enhance the brand influence of the company and have a positive impact on the company's development.The turnover of Shanghai, Shenzhen and Beijing exceeded 1 trillion yuan, 55.6 billion yuan more than the previous day. Up to now, the turnover of Shanghai, Shenzhen and Beijing exceeded 1 trillion yuan, 55.6 billion yuan more than the previous day. Among them, the turnover of Shanghai Stock Exchange was 394.6 billion yuan, that of Shenzhen Stock Exchange was 596.3 billion yuan, and that of Beizheng 50 was 11.1 billion yuan.